Keywords
- Pancreatic Cancer
- Human Pancreatic Cancer
- Karnofsky Performance Score
- Metalloproteinase Inhibition
- Unresectable Pancreatic Cancer
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Landies S, Murray T, Bolden S, Wingo P. Cancer statistics 1999. J Am Cancer Soc. 1999;49:8–31.
Koshiba T, Wada M, Fujimot K, et al. Activation of MMP-2 and MMP-9 in human pancreatic cancer tissues and human pancreatic cancer lines. Gastroenterology. 1996;110:A545.
Mignatti P, Rifkin D. Biology and biochemistry of proteinases in tumor invasion. Phys Rev. 1993;73:161–195.
Sang Q. Complex role of matrix metalloproteinases in angiogenesis. Cell Res. 1998;8:171–177.
Lozonschi L, Sunamura M, Kobari M, et al. Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models. Cancer Res. 1999;59:1252–1258.
Eccles S, Box G, Court W, et al. Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor Batimastat (BB-94). Cancer Res. 1996;56:2815–2822.
Low J, Johnson M, Bone E, Dickson R, et al. The matrix metalloproteinase inhibitor Batimastat (BB-94) retards human breast cancer solid tumor growth but not ascites formation in nude mice. Clin Cancer Res. 1996;2:1207–1214.
Watson S, Morris T, Robinson G, et al. Inhibition of organ invasion by the matrix metalloproteinase inhibitor Batimastat (BB-94) in two human colon carcinoma metastasis models. Cancer Res. 1995;55:3629–3633.
Wang X, Fu X, Brown P, et al. Matrix metalloproteinase inhibitor BB-94 (Batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res. 1994;54:4726–4728.
Davies B, Brown P, East N, et al. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res. 1993;53:2087–2091.
Giavazzi R, Garofalo A, Ferri C, et al. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts. Clin Cancer Res. 1998;4:985–992.
Chirivi R, Garofalo A, Crimmin M, et al. Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int J Cancer. 1994;58:460–466.
Wojtowicz-Praga S, Torri J, Johnson M, et al. Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J Clin Oncol. 1998;16:2150–2156.
Parsons S, Watson S, Steele R. Phase I/II trial of Batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites. Euro J Surg Oncol. 1997;23:526–531.
Zervos E, Shafii A, Rosemurgy A. Matrix metalloproteinase inhibition selectively decreases type II MMP activity in a murine model of pancreatic cancer. J Surg Res. 1999;81:65–68.
Zervos E, Shafii A, Haq M, et al. Matrix metalloproteinase inhibition suppresses MMP-2 activity and activation of PANC-1 cells in vitro. J Surg Res. 1999;84:162–167.
Zervos E, Norman J, Gower W, et al. Matrix metalloproteinase inhibition attenuates human pancreatic cancer growth in vitro and decreases mortality and tumorigenesis in vivo. J Surg Res. 1997;69:367–371.
Zervos E, Franz M, Salhab K, et al. Matrix metalloproteinase inhibition improves survival in an orthotopic model of human pancreatic cancer. J Gastrointest Surg. 2000;4:614–619.
Haq M, Shafii A, Zervos E, et al. Addition of matrix metalloproteinase inhibition to conventional cytotoxic therapy reduces tumor implantation and prolongs survival in a murine model of human pancreatic cancer. Cancer Res. 2000;60:3207–3211.
Rosemurgy A, Harris J, Langleben A, et al. Marimastat in patients with advanced pancreatic cancer: a dosefinding study. Am J Clin Oncol. 1999;22:247–252.
Burris H, Storniolo A. Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil. Eur J Cancer. 1997;33(suppl):S18–S22.
Rosemurgy A, Buckels J, Charnley R, et al. A randomized study comparing Marimastat to gemcitabine as first-line therapy in patients with non-resectable pancreatic cancer. ASCO Proceedings, Philadelphia, Pa; 1999. Abstract 1005.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer-Verlag New York, Inc.
About this chapter
Cite this chapter
Rosemurgy, A.S., Haq, M. (2002). Role of Matrix Metalloproteinase Inhibition in the Treatment of Pancreatic Cancer. In: Evans, D.B., Pisters, P.W.T., Abbruzzese, J.L. (eds) Pancreatic Cancer. M. D. Anderson Solid Tumor Oncology Series. Springer, New York, NY. https://doi.org/10.1007/0-387-21600-6_35
Download citation
DOI: https://doi.org/10.1007/0-387-21600-6_35
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-95185-0
Online ISBN: 978-0-387-21600-3
eBook Packages: Springer Book Archive